Evidence map›Paper›PMID 21816937›Full record

ArticleJournal of the American Society of Nephrology : JASN2011

Targeted inhibition of β-catenin/CBP signaling ameliorates renal interstitial fibrosis.

Sha Hao, Weichun He, Yingjian Li, Hong Ding, Yayi Hou, Jing Nie, Fan Fan Hou, Michael Kahn, Youhua Liu

Abstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers.

0numbers the graph read from it
0cells of the map it votes in
155citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

155 citing papers in PubMed, 243 citations in OpenAlex.

  1. Trial
  2. Macrophage-Fibroblast Crosstalk in Kidney Injury: A Narrative Review.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. mInternational journal of biological sciences · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Kidney fibrosis: from mechanisms to therapeutic medicines.Signal transduction and targeted therapy · 2023
    Review
  18. Article
  19. Article
  20. Review

95 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Sha HaoDepartment of Pathology, University of Pittsburgh School of Medicine, S-405 Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15261, USA.
Weichun He
Yingjian Li
Hong Ding
Yayi Hou
Jing Nie
Fan Fan Hou
Michael Kahn
Youhua Liu
University of Pittsburgh · USSouthern Medical University · CNBroad Center · USNanjing University · CN

Funding

Tenancin-C as a major component of the fibrogenic nicheR01DK064005 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAN, RODERICK JASON · 2003 to 2021
$5.1M
HGF Gene Therapy for Chronic Renal FibrosisR01DK061408 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, YOUHUA · 2002 to 2009
$1.9M
NIDDK NIH HHS DK061408NIDDK NIH HHS DK064005NIDDK NIH HHS R01 DK061408NIDDK NIH HHS R01 DK064005
6 · The paper itself

Abstract

Because fibrotic kidneys exhibit aberrant activation of β-catenin signaling, this pathway may be a potential target for antifibrotic therapy. In this study, we examined the effects of β-catenin activation on tubular epithelial-mesenchymal transition (EMT) in vitro and evaluated the therapeutic efficacy of the peptidomimetic small molecule ICG-001, which specifically disrupts β-catenin-mediated gene transcription, in obstructive nephropathy. In vitro, ectopic expression of stabilized β-catenin in tubular epithelial (HKC-8) cells suppressed E-cadherin and induced Snail1, fibronectin, and plasminogen activator inhibitor-1 (PAI-1) expression. ICG-001 suppressed β-catenin-driven gene transcription in a dose-dependent manner and abolished TGF-β1-induced expression of Snail1, PAI-1, collagen I, fibronectin, and α-smooth muscle actin (α-SMA). This antifibrotic effect of ICG-001 did not involve disruption of Smad signaling. In the unilateral ureteral obstruction model, ICG-001 ameliorated renal interstitial fibrosis and suppressed renal expression of fibronectin, collagen I, collagen III, α-SMA, PAI-1, fibroblast-specific protein-1, Snail1, and Snail2. Late administration of ICG-001 also effectively attenuated fibrotic lesions in obstructive nephropathy. In conclusion, inhibiting β-catenin signaling may be an effective approach to the treatment of fibrotic kidney diseases.

Indexed as

Epithelial-Mesenchymal Transitionbeta CateninBridged Bicyclo Compounds, HeterocyclicCell LineCREB-Binding ProteinGene Expression RegulationHumansKidney DiseasesPyrimidinonesSmad ProteinsTransforming Growth Factor beta1beta CateninBridged Bicyclo Compounds, HeterocyclicCREB-Binding ProteinICG 001PyrimidinonesSmad ProteinsTransforming Growth Factor beta1

Identifiers

PMID21816937
PMCPMC3171936
OpenAlexW2167446786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.